Literature DB >> 27504292

Anaemia in Systemic Lupus Erythematosus Based on Iron Studies and Soluble Transferrin Receptor Levels.

Salony Mittal1, Preeti Agarwal2, Anupam Wakhlu3, Ashutosh Kumar4, Raj Mehrotra5, Saumya Mittal6.   

Abstract

INTRODUCTION: Haematological alterations such as anaemia, neutropenia and thrombocytopenia are frequent in Systemic Lupus Erythematosus (SLE). Ferritin being an acute phase reactant can be falsely elevated in lupus cases. AIM: To evaluate the haematological alterations and to re-categorise the types of anemia by soluble transferrin receptor levels in diagnosed cases of SLE.
MATERIALS AND METHODS: A sample of 30 newly diagnosed ANA positive SLE patients was taken. Complete blood counts, ESR, reticulocyte count, coagulation studies, diluted Russel Viper Venom Test (dRVVT), mixing studies, serological tests, high sensitivity CRP along with iron profile, transferrin saturation, soluble transferrin receptor (sol TFR) levels, anti-beta2 glycoprotein1, direct and indirect Coomb's test were estimated in cases diagnosed as SLE. Clinical symptoms were co-related with and Systemic Lupus Erythaematosus Disease Activity Index (SLEDAI) was estimated.
RESULTS: Anaemia was the most prevalent haematological alteration followed by thrombocytopenia. Further sub typing of anaemia was done by serum ferritin levels and using sol TFR assays. Ferritin is an acute phase reactant; it underestimated iron deficiency in patients of SLE. When sol TFR was used; patients with pure Anaemia of Chronic Disease (ACD) reduced from 68% to 26%, those with pure IDA reduced from 32% to 16% and a group with co-existing IDA & ACD (58%) was defined {Agreement=53%, p=0.09} by sol TFR which co-related with clinical response to Iron therapy in these patients. CRP was significantly raised in association with disease activity. Fever (p<0.0001), arthritis (p<0.03) were significantly related and CRP was elevated (p<0.04) in cases with high SLEDAI (severe flare).
CONCLUSION: Thus, in SLE, anaemia is the most frequent hematological alteration; iron deficiencies supercede in contrast to ACD and further autoimmune haemolytic anaemia. Sol TFR emerged as a better parameter to detect iron deficiency in patients of non- haemolytic anaemia in contrast to iron profile and ferritin levels.

Entities:  

Keywords:  Anaemia of chronic disease; Arthritis; C-reactive protein; Coagulation test; Ferritin; Fever; Iron deficiency anaemia; Iron profile; Soluble transferrin receptor

Year:  2016        PMID: 27504292      PMCID: PMC4963652          DOI: 10.7860/JCDR/2016/17930.7961

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  15 in total

1.  Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin.

Authors:  M Voulgarelis; S I Kokori; J P Ioannidis; A G Tzioufas; D Kyriaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

2.  Evaluation of serum transferrin receptor and sTfR ferritin indices in diagnosing and differentiating iron deficiency anemia from anemia of chronic disease.

Authors:  Shilpa Jain; Shashi Narayan; Jagdish Chandra; Sunita Sharma; Sonal Jain; Priya Malhan
Journal:  Indian J Pediatr       Date:  2010-01-20       Impact factor: 1.967

3.  C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus.

Authors:  Luis M Amezcua-Guerra; Rashidi Springall; Angel A Arrieta-Alvarado; Verónica Rodríguez; Eduardo Rivera-Martinez; Diana Castillo-Martinez; Rafael Bojalil
Journal:  Clin Lab       Date:  2011       Impact factor: 1.138

4.  Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations.

Authors:  A E Mast; M A Blinder; A M Gronowski; C Chumley; M G Scott
Journal:  Clin Chem       Date:  1998-01       Impact factor: 8.327

Review 5.  The role of sex hormones in systemic lupus erythematosus.

Authors:  R G Lahita
Journal:  Curr Opin Rheumatol       Date:  1999-09       Impact factor: 5.006

6.  [Relations beetwen severity of anemia and certain antiphospholipid antibodies presence in systemic lupus erythematosus patients].

Authors:  Dorota Suszek; Maria Majdan; Dariusz Chudzik; Magdalena Dryglewska
Journal:  Pol Arch Med Wewn       Date:  2006-05

7.  Frequency of anaemia in patients with systemic lupus erythematosus at tertiary care hospitals.

Authors:  Mumtaz Ali Shaikh; Iqbal Memon; Rafi Ahmed Ghori
Journal:  J Pak Med Assoc       Date:  2010-10       Impact factor: 0.781

Review 8.  Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment.

Authors:  S Giannouli; M Voulgarelis; P D Ziakas; A G Tzioufas
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

9.  Systemic lupus erythematosus.

Authors:  Susanne M Benseler; Earl D Silverman
Journal:  Rheum Dis Clin North Am       Date:  2007-08       Impact factor: 2.670

Review 10.  Systemic lupus erythematosus.

Authors:  Jessica J Manson; Anisur Rahman
Journal:  Orphanet J Rare Dis       Date:  2006-03-27       Impact factor: 4.123

View more
  3 in total

1.  Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico City.

Authors:  Pedro Torres-González; Juanita Romero-Díaz; Miguel Enrique Cervera-Hernández; Mario Ocampo-Torres; Luis Gerardo Chaires-Garza; Ernesto Alejandro Lastiri-González; Yemil Atisha-Fregoso; Miriam Bobadilla-Del-Valle; Alfredo Ponce-de-León; José Sifuentes-Osornio
Journal:  Clin Rheumatol       Date:  2018-04-20       Impact factor: 2.980

2.  Associated clinical factors for serious infections in patients with systemic lupus erythematosus.

Authors:  Ju-Yang Jung; Dukyong Yoon; Young Choi; Hyoun-Ah Kim; Chang-Hee Suh
Journal:  Sci Rep       Date:  2019-07-04       Impact factor: 4.379

Review 3.  A Practical Perspective of the Hematologic Manifestations of Systemic Lupus Erythematosus.

Authors:  Juan Camilo Santacruz; Marta Juliana Mantilla; Igor Rueda; Sandra Pulido; Gustavo Rodriguez-Salas; John Londono
Journal:  Cureus       Date:  2022-03-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.